desiccated thyroid extract (DTE)+levothyroxine (L-T4)
2025(1862)
Phase 3 small_molecule active
Quick answer
desiccated thyroid extract (DTE)+levothyroxine (L-T4) for Intermediate-to-High Risk Differentiated Thyroid Cancer is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Intermediate-to-High Risk Differentiated Thyroid Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active